Citadel Advisors’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-31,418
| Closed | -$368K | – | 13713 |
|
|
2025
Q4 | $468K | Buy |
31,418
+533
| +2% | +$9.3K | ﹤0.01% | 9187 |
|
|
2025
Q3 | $594K | Buy |
+30,885
| New | +$493K | ﹤0.01% | 8705 |
|
|
2025
Q2 | – | Sell |
-2
| Closed | -$18 | – | 14029 |
|
|
2025
Q1 | $34 | Hold |
2
| – | – | ﹤0.01% | 14349 |
|
|
2024
Q4 | $26 | Buy |
+2
| New | +$33 | ﹤0.01% | 14397 |
|
|
2024
Q2 | – | Sell |
-224
| Closed | -$3.74K | – | 14962 |
|
|
2024
Q1 | $3.47K | Buy |
224
+170
| +315% | +$3.67K | ﹤0.01% | 13901 |
|
|
2023
Q4 | $1.52K | Sell |
54
-9,340
| -99% | -$245K | ﹤0.01% | 13812 |
|
|
2023
Q3 | $447K | Buy |
9,394
+7,305
| +350% | +$557K | ﹤0.01% | 8295 |
|
|
2023
Q2 | $200K | Sell |
2,089
-24,396
| -92% | -$2.65M | ﹤0.01% | 9892 |
|
|
2023
Q1 | $3M | Buy |
26,485
+26,354
| +20,118% | +$2.85M | ﹤0.01% | 4632 |
|
|
2022
Q4 | $14.7K | Sell |
131
-1,548
| -92% | -$208K | ﹤0.01% | 13376 |
|
|
2022
Q3 | $216K | Sell |
1,679
-6,526
| -80% | -$668K | ﹤0.01% | 10260 |
|
|
2022
Q2 | $563K | Sell |
8,205
-3,644
| -31% | -$314K | ﹤0.01% | 8385 |
|
|
2022
Q1 | $1.69M | Sell |
11,849
-7,938
| -40% | -$1.22M | ﹤0.01% | 6471 |
|
|
2021
Q4 | $3.3M | Buy |
19,787
+15,027
| +316% | +$2.39M | ﹤0.01% | 5151 |
|
|
2021
Q3 | $663K | Sell |
4,760
-9,203
| -66% | -$1.8M | ﹤0.01% | 9197 |
|
|
2021
Q2 | $6.66M | Sell |
13,963
-3,047
| -18% | -$1.29M | ﹤0.01% | 3848 |
|
|
2021
Q1 | $7M | Buy |
17,010
+2,531
| +17% | +$1.17M | ﹤0.01% | 3577 |
|
|
2020
Q4 | $7.09M | Buy |
14,479
+10,863
| +300% | +$6.36M | ﹤0.01% | 3104 |
|
|
2020
Q3 | $2.05M | Buy |
3,616
+1,999
| +124% | +$665K | ﹤0.01% | 4664 |
|
|
2020
Q2 | $154K | Sell |
1,617
-644
| -28% | -$56.5K | ﹤0.01% | 8722 |
|
|
2020
Q1 | $161K | Sell |
2,261
-176
| -7% | -$11.8K | ﹤0.01% | 8224 |
|
|
2019
Q4 | $168K | Buy |
2,437
+1,542
| +172% | +$114K | ﹤0.01% | 8299 |
|
|
2019
Q3 | $72K | Sell |
895
-2,387
| -73% | -$158K | ﹤0.01% | 8609 |
|
|
2019
Q2 | $212K | Buy |
3,282
+2,489
| +314% | +$236K | ﹤0.01% | 8111 |
|
|
2019
Q1 | $109K | Sell |
793
-1,428
| -64% | -$174K | ﹤0.01% | 8519 |
|
|
2018
Q4 | $200K | Buy |
2,221
+651
| +41% | +$91.1K | ﹤0.01% | 7859 |
|
|
2018
Q3 | $239K | Buy |
1,570
+509
| +48% | +$82.3K | ﹤0.01% | 7955 |
|
|
2018
Q2 | $183K | Sell |
1,061
-5,785
| -85% | -$945K | ﹤0.01% | 7956 |
|
|
2018
Q1 | $1M | Sell |
6,846
-37
| -0.5% | -$7.1K | ﹤0.01% | 4797 |
|
|
2017
Q4 | $1.4M | Buy |
+6,883
| New | +$1.41M | ﹤0.01% | 4136 |
|
|
2017
Q3 | – | Sell |
-2,011
| Closed | -$455K | – | 7818 |
|
|
2017
Q2 | $455K | Buy |
2,011
+978
| +95% | +$201K | ﹤0.01% | 5259 |
|
|
2017
Q1 | $233K | Buy |
1,033
+442
| +75% | +$89.7K | ﹤0.01% | 6283 |
|
|
2016
Q4 | $117K | Sell |
591
-4,116
| -87% | -$898K | ﹤0.01% | 6609 |
|
|
2016
Q3 | $1.16M | Buy |
+4,707
| New | +$1.65M | ﹤0.01% | 3645 |
|
|
2015
Q3 | – | Sell |
-9,661
| Closed | -$8.02M | – | 9088 |
|
|
2015
Q2 | $8.02M | Buy |
+9,661
| New | +$8.43M | 0.01% | 1616 |
|
Other funds holding MCRB
FP
VCM
VFT
Citadel Advisors's MCRB Position: Q1 2026 in Review
Citadel Advisors sold out of Seres Therapeutics (MCRB) in Q1 2026, closing a stake of 31,418 shares — an estimated $368K sold.
Citadel Advisors first reported a position in MCRB in Q2 2015 and held it in 35 quarters. The position peaked at $8.02M in Q2 2015. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.
- Citadel Advisors reported no remaining Seres Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 31,418 Seres Therapeutics shares in Q1 2026, an estimated $368K.
- Citadel Advisors first reported a position in Seres Therapeutics in Q2 2015 and held it in 35 quarters.
- Citadel Advisors's Seres Therapeutics position peaked at $8.02M in Q2 2015.
- 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.